{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T22:47:36Z","timestamp":1792450056047,"version":"4.5.0"},"reference-count":90,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.jtho.2021.12.014","type":"journal-article","created":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T12:02:07Z","timestamp":1641816127000},"page":"608-622","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":194,"title":["The 2021 WHO Classification of Tumors of the Pleura: Advances Since the 2015 Classification"],"prefix":"10.1016","volume":"17","author":[{"given":"Jennifer L.","family":"Sauter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanja","family":"Dacic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francoise","family":"Galateau-Salle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard L.","family":"Attanoos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly J.","family":"Butnor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Churg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aliya N.","family":"Husain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyuichi","family":"Kadota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andras","family":"Khoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew G.","family":"Nicholson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Roggli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Sound","family":"Tsao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William D.","family":"Travis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2021.12.014_bib1","series-title":"WHO Classification of Tumours: Thoracic Tumours","year":"2021"},{"key":"10.1016\/j.jtho.2021.12.014_bib2","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1097\/JTO.0000000000000663","article-title":"Introduction to the 2015 World Health Organization classification of tumors of the lung, pleura, thymus, and heart","volume":"10","author":"Travis","year":"2015","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2021.12.014_bib3","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1097\/00000478-200110000-00012","article-title":"Well-differentiated papillary mesothelioma","volume":"25","author":"Butnor","year":"2001","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.jtho.2021.12.014_bib4","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1097\/00000478-200404000-00013","article-title":"Well-differentiated papillary mesothelioma of the pleura: a series of 24 cases","volume":"28","author":"Galateau-Sall\u00e9","year":"2004","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.jtho.2021.12.014_bib5","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/s41379-019-0352-3","article-title":"Localized malignant mesothelioma, an unusual and poorly characterized neoplasm of serosal origin: best current evidence from the literature and the International Mesothelioma Panel","volume":"33","author":"Marchevsky","year":"2020","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jtho.2021.12.014_bib6","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jtho.2015.11.005","article-title":"The 2015 World Health Organization classification of tumors of the pleura: advances since the 2004 classification","volume":"11","author":"Galateau-Salle","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2021.12.014_bib7","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.humpath.2018.05.001","article-title":"BAP1 loss is unusual in well-differentiated papillary mesothelioma and may predict development of malignant mesothelioma","volume":"79","author":"Lee","year":"2018","journal-title":"Hum Pathol"},{"key":"10.1016\/j.jtho.2021.12.014_bib8","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/s41379-019-0347-0","article-title":"Malignant mesothelioma in situ: morphologic features and clinical outcome","volume":"33","author":"Churg","year":"2020","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jtho.2021.12.014_bib9","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1111\/his.13468","article-title":"Malignant mesothelioma in situ","volume":"72","author":"Churg","year":"2018","journal-title":"Histopathology"},{"key":"10.1016\/j.jtho.2021.12.014_bib10","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00428-019-02674-x","article-title":"Malignant mesothelioma in situ diagnosed by methylthioadenosine phosphorylase loss and homozygous deletion of CDKN2A: a case report","volume":"476","author":"Minami","year":"2020","journal-title":"Virchows Arch"},{"key":"10.1016\/j.jtho.2021.12.014_bib11","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1200\/JCO.1998.16.1.145","article-title":"Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience","volume":"16","author":"Curran","year":"1998","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2021.12.014_bib12","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.jtcvs.2008.02.069","article-title":"The impact of lymph node station on survival in 348 patients with surgically resected malignant pleural mesothelioma: implications for revision of the American Joint Committee on Cancer staging system","volume":"136","author":"Flores","year":"2008","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"key":"10.1016\/j.jtho.2021.12.014_bib13","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jss.2015.01.043","article-title":"Impact of mesothelioma histologic subtype on outcomes in the Surveillance, Epidemiology, and End Results database","volume":"196","author":"Meyerhoff","year":"2015","journal-title":"J\u00a0Surg Res"},{"key":"10.1016\/j.jtho.2021.12.014_bib14","first-page":"523","article-title":"Extrapleural pneumonectomy and extended pleurectomy\/decortication for malignant pleural mesothelioma: the Memorial Sloan-Kettering Cancer Center approach","volume":"1","author":"Rusch","year":"2012","journal-title":"Ann Cardiothorac Surg"},{"key":"10.1016\/j.jtho.2021.12.014_bib15","first-page":"438","article-title":"Do we need a revised staging system for malignant pleural mesothelioma? Analysis of the IASLC database","volume":"1","author":"Rusch","year":"2012","journal-title":"Ann Cardiothorac Surg"},{"key":"10.1016\/j.jtho.2021.12.014_bib16","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1097\/JTO.0b013e31826915f1","article-title":"Initial analysis of the international association for the study of lung cancer mesothelioma database","volume":"7","author":"Rusch","year":"2012","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2021.12.014_bib17","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/JTO.0000000000000122","article-title":"The challenge of malignant pleural mesothelioma: new directions","volume":"9","author":"Rusch","year":"2014","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2021.12.014_bib18","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1016\/S0003-4975(99)01038-3","article-title":"Important prognostic factors in patients with malignant pleural mesothelioma, managed surgically","volume":"68","author":"Rusch","year":"1999","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.jtho.2021.12.014_bib19","doi-asserted-by":"crossref","first-page":"6881","DOI":"10.1200\/JCO.20005.14.589","volume":"23","author":"van Meerbeeck","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2021.12.014_bib20","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jtho.2019.08.2506","article-title":"EURACAN\/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach","volume":"15","author":"Nicholson","year":"2020","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2021.12.014_bib21","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/modpathol.2011.146","article-title":"A\u00a0nuclear grading system is a strong predictor of survival in epitheloid diffuse malignant pleural mesothelioma","volume":"25","author":"Kadota","year":"2012","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jtho.2021.12.014_bib22","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/modpathol.2017.170","article-title":"Nuclear grade and necrosis predict prognosis in malignant epithelioid pleural mesothelioma: a multi-institutional study","volume":"31","author":"Rosen","year":"2018","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jtho.2021.12.014_bib23","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1365-2559.1992.tb00915.x","article-title":"The histology and immunohistochemistry of small cell mesothelioma","volume":"20","author":"Mayall","year":"1992","journal-title":"Histopathology"},{"key":"10.1016\/j.jtho.2021.12.014_bib24","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/modpathol.2011.202","article-title":"Mesotheliomas with small cell features: report of eight cases","volume":"25","author":"Ord\u00f3\u00f1ez","year":"2012","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jtho.2021.12.014_bib25","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1136\/jclinpath-2016-203993","article-title":"Myxoid variant epithelioid pleural mesothelioma defines a favourable prognosis group: an analysis of 191 patients with pleural malignant mesothelioma","volume":"70","author":"Alchami","year":"2017","journal-title":"J\u00a0Clin Pathol"},{"key":"10.1016\/j.jtho.2021.12.014_bib26","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1007\/s00428-005-0035-y","article-title":"Malignant mesothelioma with a pronounced myxoid stroma: a clinical and pathological evaluation of 19 cases","volume":"447","author":"Shia","year":"2005","journal-title":"Virchows Arch"},{"key":"10.1016\/j.jtho.2021.12.014_bib27","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1097\/JTO.0b013e318211127a","article-title":"Pleomorphic epithelioid diffuse malignant pleural mesothelioma: a clinicopathological review and conceptual proposal to reclassify as biphasic or sarcomatoid mesothelioma","volume":"6","author":"Kadota","year":"2011","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2021.12.014_bib28","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/modpathol.3800543","article-title":"Mesothelioma with rhabdoid features: an ultrastructural and immunohistochemical study of 10 cases","volume":"19","author":"Ord\u00f3\u00f1ez","year":"2006","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jtho.2021.12.014_bib29","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/modpathol.2012.39","article-title":"Pleomorphic mesothelioma: report of 10 cases","volume":"25","author":"Ord\u00f3\u00f1ez","year":"2012","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jtho.2021.12.014_bib30","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1097\/PAS.0b013e31802baad7","article-title":"Lymphohistiocytoid variant of malignant mesothelioma of the pleura: a series of 22 cases","volume":"31","author":"Galateau-Sall\u00e9","year":"2007","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.jtho.2021.12.014_bib31","doi-asserted-by":"crossref","first-page":"367","DOI":"10.3109\/01913128809064207","article-title":"Lymphohistiocytoid mesothelioma: a rare lymphomatoid variant of predominantly sarcomatoid mesothelioma","volume":"12","author":"Henderson","year":"1988","journal-title":"Ultrastruct Pathol"},{"key":"10.1016\/j.jtho.2021.12.014_bib32","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1111\/j.1440-1827.2010.02560.x","article-title":"Lymphohistiocytoid mesothelioma of the pleura","volume":"60","author":"Kawai","year":"2010","journal-title":"Pathol Int"},{"key":"10.1016\/j.jtho.2021.12.014_bib33","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1080\/019131290505176","article-title":"Lymphohistiocytoid mesothelioma: a clinical, immunohistochemical and ultrastructural study of four cases and literature review","volume":"28","author":"Yao","year":"2004","journal-title":"Ultrastruct Pathol"},{"key":"10.1016\/j.jtho.2021.12.014_bib34","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.lungcan.2018.07.041","article-title":"Highlights of the 14th international mesothelioma interest group meeting: pathologic separation of benign from malignant mesothelial proliferations and histologic\/molecular analysis of malignant mesothelioma subtypes","volume":"124","author":"Churg","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2021.12.014_bib35","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1038\/s41591-019-0583-3","article-title":"Deep learning-based classification of mesothelioma improves prediction of patient outcome","volume":"25","author":"Courtiol","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.jtho.2021.12.014_bib36","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41379-019-0320-y","article-title":"Interobserver variation in the assessment of the sarcomatoid and transitional components in biphasic mesotheliomas","volume":"33","author":"Dacic","year":"2020","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jtho.2021.12.014_bib37","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.jtho.2020.01.025","article-title":"Comprehensive molecular and pathologic evaluation of transitional mesothelioma assisted by deep learning approach: a multi-institutional study of the international mesothelioma panel from the MESOPATH Reference Center","volume":"15","author":"Galateau Salle","year":"2020","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2021.12.014_bib38","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/PAS.0000000000001416","article-title":"Utility of nuclear grading system in epithelioid malignant pleural mesothelioma in biopsy-heavy setting: an external validation study of 563 cases","volume":"44","author":"Zhang","year":"2020","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.jtho.2021.12.014_bib39","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/cncy.21392","article-title":"Claudin-4 immunohistochemistry is highly effective in distinguishing adenocarcinoma from malignant mesothelioma in effusion cytology","volume":"122","author":"Jo","year":"2014","journal-title":"Cancer Cytopathol"},{"key":"10.1016\/j.jtho.2021.12.014_bib40","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.jasc.2019.12.003","article-title":"Utility of Claudin-4 versus BerEP4 and B72.3 in pleural fluids with metastatic lung adenocarcinoma","volume":"9","author":"Patel","year":"2020","journal-title":"J\u00a0Am Soc Cytopathol"},{"key":"10.1016\/j.jtho.2021.12.014_bib41","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1136\/jcp.2005.028589","article-title":"Claudins in differential diagnosis between mesothelioma and metastatic adenocarcinoma of the pleura","volume":"59","author":"Soini","year":"2006","journal-title":"J\u00a0Clin Pathol"},{"key":"10.1016\/j.jtho.2021.12.014_bib42","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1159\/000501406","article-title":"Diagnostic value of the EZH2 immunomarker in malignant effusion cytology","volume":"64","author":"Ang","year":"2020","journal-title":"Acta Cytol"},{"key":"10.1016\/j.jtho.2021.12.014_bib43","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/ng.855","article-title":"The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma","volume":"43","author":"Bott","year":"2011","journal-title":"Nat Genet"},{"key":"10.1016\/j.jtho.2021.12.014_bib44","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.5858\/arpa.2012-0112-RA","article-title":"The separation of benign and malignant mesothelial proliferations","volume":"136","author":"Churg","year":"2012","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.jtho.2021.12.014_bib45","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1097\/PAS.0000000000000616","article-title":"BAP1 Immunohistochemistry and p16 FISH in the diagnosis of sarcomatous and desmoplastic mesotheliomas","volume":"40","author":"Hwang","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.jtho.2021.12.014_bib46","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1309\/AJCPP5R2ZJZKCLWN","article-title":"The diagnostic utility of p16 FISH and GLUT-1 immunohistochemical analysis in mesothelial proliferations","volume":"135","author":"Monaco","year":"2011","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.jtho.2021.12.014_bib47","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/his.13123","article-title":"Diagnostic utility of BAP1 and EZH2 expression in malignant mesothelioma","volume":"70","author":"Shinozaki-Ushiku","year":"2017","journal-title":"Histopathology"},{"key":"10.1016\/j.jtho.2021.12.014_bib48","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/ng.912","article-title":"Germline BAP1 mutations predispose to malignant mesothelioma","volume":"43","author":"Testa","year":"2011","journal-title":"Nat Genet"},{"key":"10.1016\/j.jtho.2021.12.014_bib49","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.lungcan.2019.02.004","article-title":"Highly expressed EZH2 in combination with BAP1 and MTAP loss, as detected by immunohistochemistry, is useful for differentiating malignant pleural mesothelioma from reactive mesothelial hyperplasia","volume":"130","author":"Yoshimura","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2021.12.014_bib50","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/cncr.10923","article-title":"The use of CDKN2A deletion as a diagnostic marker for malignant mesothelioma in body cavity effusions","volume":"99","author":"Illei","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.jtho.2021.12.014_bib51","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.5858\/arpa.2018-0273-OA","article-title":"Utility of methylthioadenosine phosphorylase compared with BAP1 immunohistochemistry, and CDKN2A and NF2 fluorescence in situ hybridization in separating reactive mesothelial proliferations from epithelioid malignant mesotheliomas","volume":"142","author":"Berg","year":"2018","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.jtho.2021.12.014_bib52","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.5858\/arpa.2013-0610-CP","article-title":"Principles of analytic validation of immunohistochemical assays: guideline from the College of American Pathologists Pathology and Laboratory Quality Center","volume":"138","author":"Fitzgibbons","year":"2014","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.jtho.2021.12.014_bib53","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/cncy.21660","article-title":"Young investigator challenge: validation and optimization of immunohistochemistry protocols for use on cellient cell block specimens","volume":"124","author":"Sauter","year":"2016","journal-title":"Cancer Cytopathol"},{"key":"10.1016\/j.jtho.2021.12.014_bib54","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1002\/cncy.22170","article-title":"CytoLyt fixation significantly inhibits MIB1 immunoreactivity whereas alternative Ki-67 clone 30-9 is not susceptible to the inhibition: critical diagnostic implications","volume":"127","author":"Buonocore","year":"2019","journal-title":"Cancer Cytopathol"},{"key":"10.1016\/j.jtho.2021.12.014_bib55","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/cncy.22137","article-title":"Immunocytochemistry for predictive biomarker testing in lung cancer cytology","volume":"127","author":"Jain","year":"2019","journal-title":"Cancer Cytopathol"},{"key":"10.1016\/j.jtho.2021.12.014_bib56","doi-asserted-by":"crossref","first-page":"241","DOI":"10.5858\/arpa.2013-0953-SA","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update","volume":"138","author":"Wolff","year":"2014","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.jtho.2021.12.014_bib57","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/modpathol.3880368","article-title":"Proximal-type epithelioid sarcoma: a clinicopathologic study of 20 cases","volume":"14","author":"Hasegawa","year":"2001","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jtho.2021.12.014_bib58","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/ng.3399","article-title":"SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas","volume":"47","author":"Le Loarer","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.jtho.2021.12.014_bib59","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1097\/PAS.0000000000001188","article-title":"SMARCA4-deficient thoracic sarcomas: clinicopathologic study of 30 cases with an emphasis on their nosology and differential diagnoses","volume":"43","author":"Perret","year":"2019","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.jtho.2021.12.014_bib60","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jtho.2019.10.023","article-title":"SMARCA4-deficient thoracic sarcomatoid tumors represent primarily smoking-related undifferentiated carcinomas rather than primary thoracic sarcomas","volume":"15","author":"Rekhtman","year":"2020","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2021.12.014_bib61","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/modpathol.2017.11","article-title":"Clinicopathological and molecular characterization of SMARCA4-deficient thoracic sarcomas with comparison to potentially related entities","volume":"30","author":"Yoshida","year":"2017","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jtho.2021.12.014_bib62","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1038\/modpathol.2017.61","article-title":"SMARCA4-deficient thoracic sarcoma: a distinctive clinicopathological entity with undifferentiated rhabdoid mrophology and\u00a0aggressive behaviro","volume":"30","author":"Sauter","year":"2017","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jtho.2021.12.014_bib63","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/ng.3520","article-title":"Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations","volume":"48","author":"Bueno","year":"2016","journal-title":"Nat Genet"},{"key":"10.1016\/j.jtho.2021.12.014_bib64","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1158\/2159-8290.CD-18-0804","article-title":"integrative molecular characterization of malignant pleural mesothelioma","volume":"8","author":"Hmeljak","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2021.12.014_bib65","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1038\/s41467-019-09307-6","article-title":"Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications","volume":"10","author":"Blum","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtho.2021.12.014_bib66","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ebiom.2019.09.003","article-title":"Redefining malignant pleural mesothelioma types as a continuum uncovers immune-vascular interactions","volume":"48","author":"Alcala","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.jtho.2021.12.014_bib67","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1002\/1878-0261.12651","article-title":"Genetic alterations of malignant pleural mesothelioma: association with tumor heterogeneity and overall survival","volume":"14","author":"Quetel","year":"2020","journal-title":"Mol Oncol"},{"key":"10.1016\/j.jtho.2021.12.014_bib68","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s13073-021-00931-w","article-title":"Multi-site tumor sampling highlights molecular intra-tumor heterogeneity in malignant pleural mesothelioma","volume":"13","author":"Meiller","year":"2021","journal-title":"Genome Med"},{"key":"10.1016\/j.jtho.2021.12.014_bib69","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41379-021-00900-z","article-title":"Molecular characterization of pleomorphic mesothelioma: a multi-institutional study","volume":"35","author":"Roy","year":"2022","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jtho.2021.12.014_bib70","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.lungcan.2018.03.009","article-title":"Malignant cells from pleural fluids in malignant mesothelioma patients reveal novel mutations","volume":"119","author":"Sneddon","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2021.12.014_bib71","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1097\/JTO.0000000000000436","article-title":"Targeted next-generation sequencing of cancer genes in advanced stage malignant pleural mesothelioma: a retrospective study","volume":"10","author":"Lo Iacono","year":"2015","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2021.12.014_bib72","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1200\/JCO.2017.76.6394","article-title":"Treatment of malignant pleural mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Kindler","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2021.12.014_bib73","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.3389\/fonc.2019.01519","article-title":"Malignant pleural mesothelioma: state-of-the-art on current therapies and promises for the future","volume":"9","author":"Nicolini","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.jtho.2021.12.014_bib74","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1038\/modpathol.2008.45","article-title":"Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas","volume":"21","author":"Chiosea","year":"2008","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jtho.2021.12.014_bib75","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1097\/PAS.0000000000000864","article-title":"A\u00a0subset of malignant mesotheliomas in young adults are associated with recurrent EWSR1\/FUS-ATF1 fusions","volume":"41","author":"Desmeules","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.jtho.2021.12.014_bib76","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.21037\/tlcr-20-673","article-title":"Immunotherapy in malignant pleural mesothelioma: a review of literature data","volume":"10","author":"Menis","year":"2021","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.jtho.2021.12.014_bib77","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S2213-2600(18)30420-X","article-title":"Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial","volume":"7","author":"Disselhorst","year":"2019","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jtho.2021.12.014_bib78","doi-asserted-by":"crossref","first-page":"684025","DOI":"10.3389\/fonc.2021.684025","article-title":"Immune microenvironment and genetics in malignant pleural mesothelioma","volume":"11","author":"Wadowski","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.jtho.2021.12.014_bib79","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.3390\/cancers13112564","article-title":"Pathological characterization of Tumor Immune Microenvironment (TIME) in malignant pleural mesothelioma","volume":"13","author":"Napoli","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jtho.2021.12.014_bib80","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.21037\/tlcr-20-1114","article-title":"Prognostic impact of PD-1 and PD-L1 expression in malignant pleural mesothelioma: an international multicenter study","volume":"10","author":"Brcic","year":"2021","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.jtho.2021.12.014_bib81","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.lungcan.2020.09.026","article-title":"Characterization of the immune microenvironment in malignant pleural mesothelioma reveals prognostic subgroups of patients","volume":"150","author":"Fusco","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2021.12.014_bib82","doi-asserted-by":"crossref","first-page":"e564","DOI":"10.1016\/j.cllc.2019.04.010","article-title":"Shorter survival in malignant pleural mesothelioma patients with high PD-L1 expression associated with sarcomatoid or biphasic histology subtype: a series of 214 cases from the Bio-MAPS cohort","volume":"20","author":"Brosseau","year":"2019","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.jtho.2021.12.014_bib83","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1007\/s11033-019-04715-9","article-title":"Tumour infiltrating lymphocytes and PD-L1 expression as potential predictors of outcome in patients with malignant pleural mesothelioma","volume":"46","author":"Sobhani","year":"2019","journal-title":"Mol Biol Rep"},{"key":"10.1016\/j.jtho.2021.12.014_bib84","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.humpath.2016.01.010","article-title":"Immune biomarkers PD-1\/PD-L1 and TLR3 in malignant pleural mesotheliomas","volume":"52","author":"Combaz-Lair","year":"2016","journal-title":"Hum Pathol"},{"key":"10.1016\/j.jtho.2021.12.014_bib85","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/s41379-019-0364-z","article-title":"V-domain Ig-containing suppressor of T-cell activation (VISTA), a potentially targetable immune checkpoint molecule, is highly expressed in epithelioid malignant pleural mesothelioma","volume":"33","author":"Muller","year":"2020","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jtho.2021.12.014_bib86","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/s41379-019-0330-9","article-title":"Molecular characterization of localized pleural mesothelioma","volume":"33","author":"Hung","year":"2020","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jtho.2021.12.014_bib87","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/modpathol.2017.153","article-title":"Adenomatoid tumors of the male and female genital tract are defined by TRAF7 mutations that drive aberrant NF-kB pathway activation","volume":"31","author":"Goode","year":"2018","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jtho.2021.12.014_bib88","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1097\/00000478-199610000-00007","article-title":"Adenomatoid tumors of the pleura","volume":"20","author":"Kaplan","year":"1996","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.jtho.2021.12.014_bib89","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/0140-6736(91)90399-A","article-title":"European drug regulation","volume":"338","author":"Kelly","year":"1991","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2021.12.014_bib90","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/j.1440-1827.2009.02407.x","article-title":"Adenomatoid tumor of the pleura","volume":"59","author":"Minato","year":"2009","journal-title":"Pathol Int"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086422000260?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086422000260?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:48:20Z","timestamp":1761562100000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086422000260"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":90,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S1556086422000260"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2021.12.014","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The 2021 WHO Classification of Tumors of the Pleura: Advances Since the 2015 Classification","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2021.12.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 International Association for the Study of Lung Cancer. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}